降脂药对认知表现有危害吗? :一个门德尔的随机化研究
Lijun Han1,2,3,4,5,6, Chang Su1,2,3,4,5,6, Ruonan Lian1,2,3,4,5,6
1Key Laboratory of Endocrine Glucose & Lipids Metabolism and Brain Aging, Ministry of Education; Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, China.
Medicine
|September 9, 2025
概括
心血管疾病影响认知. 这项研究发现,他类药物和ezetimibe可能会对认知表现产生负面影响,而PCSK9抑制剂和纤维酸药物没有显著影响,有助于临床决策.
科学领域:
- 心血管疾病的研究研究.
- 神经科学是一个神经科学.
- 药物基因组学 药物基因组学
背景情况:
- 心血管疾病 (CVD) 是全球主要的死亡原因,与老年人认知障碍有关.
- 降脂药物对心血管疾病管理至关重要,但它们对认知的影响仍然受到争论,因为研究结果相互矛盾.
- 了解不同类型的降脂药物对认知功能的精确影响,对于临床实践至关重要.
研究的目的:
- 使用孟德尔的随机化方法,研究各种降脂药物和认知表现之间的因果关系.
- 为临床医生提供基于证据的指导,帮助他们选择适当的降脂疗法,以解决认知副作用的问题.
- 为了区分常规处方的降脂药物的认知影响.
主要方法:
- 一个双样本的门德尔随机化研究,利用全基因组关联研究总结统计数据.
- 仪器变量是与脂质水平 (LDL胆固醇,甘油三) 和药物向基因相关的单核酸多态.
- 替代品用于他类药物,埃泽提米布,蛋白转化酶亚素/素9型 (PCSK9) 抑制剂和纤维化物.
主要成果:
- 基因预测的他类药物的使用对认知表现产生了不良影响 (β = -0.094,P < .001).
- 埃泽胺使用也与对认知的显著不良影响有关 (β = -0.319,P < .001).
- 对于PCSK9抑制剂和纤维化物,没有观察到对认知表现的显著影响.
结论:
- 类药物和ezetimibe可能会对认知功能产生负面影响,因此在处方时需要仔细考虑.
- PCSK9抑制剂和纤维酸似乎对认知有中性的影响,为某些患者群体提供更安全的替代品.
- 需要进一步的长期临床研究来验证这些发现,并为认知健康的降脂药物选择提供临床指南.
相关概念视频
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
563
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
563
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
01:26Atherosclerosis III: Management
322
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
322
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
257
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
257
01:21Factors Affecting Drug Response: Overview
3.0K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
3.0K